MGMT and central nervous system cancer: Glioma patients with both the IDH1 mutation and MGMT methylation (3.0% of all patients) had the best overall survival, followed by patients with an IDH1 mutation and unmethylated MGMT promoter (1.0%), then by patients with MGMT promoter methylation and IDH1 wildtype (55.4%).